Cytokinetics seeks FDA label update for Myqorzo with Maple-HCM data

Cytokinetics is seeking an FDA label update for Myqorzo, its approved hypertrophic cardiomyopathy treatment, to incorporate findings from its Phase 3 Maple-HCM trial. The trial showed patients on Myqorzo achieved significantly greater exercise-capacity improvements after 24 weeks than those on metoprolol, with a 2.3 ml/kg/min gain in peak oxygen consumption.

Detected & updated continuously · Source: Nebula